Sertindole is an atypical antipsychotic medication that belongs to the diphenylbutylpiperidine class of compounds. It is primarily indicated for the treatment of schizophrenia in adults and is marketed under trade names such as Serlect and Sertindole® in various countries.
Pharmacology
- Mechanism of action: Sertindole functions as a dopamine D₂ receptor antagonist with high affinity, while also exhibiting antagonistic activity at serotonin 5‑HT₂A receptors, α₁‑adrenergic receptors, and histamine H₁ receptors. Its receptor profile is thought to contribute to both antipsychotic efficacy and the side‑effect spectrum.
- Pharmacokinetics: After oral administration, sertindole is well absorbed, reaching peak plasma concentrations within 2–4 hours. It is highly protein‑bound (> 99 %) and undergoes extensive hepatic metabolism, principally via CYP3A4, producing inactive metabolites. The elimination half‑life ranges from 60 to 70 hours, permitting once‑daily dosing. Excretion occurs mainly via feces, with a minor renal component.
Medical uses
- Schizophrenia: Sertindole is prescribed for the management of positive, negative, and cognitive symptoms of schizophrenia, particularly in patients who have not responded adequately to other antipsychotics. Clinical trials have demonstrated efficacy comparable to haloperidol and risperidone in reducing psychotic symptoms.
Regulatory status
- European Union: Sertindole received marketing authorization in the EU in 1998 (initially under the name Serlect). In 2002, the European Medicines Agency (EMA) suspended its use due to concerns regarding QT interval prolongation and the risk of serious cardiac arrhythmias. The suspension was lifted in 2004 after the implementation of a risk‑management plan and stricter monitoring requirements.
- United States: Sertindole has never been approved by the U.S. Food and Drug Administration (FDA). Applications submitted by the manufacturer were not pursued to approval, primarily because of safety concerns.
- Other regions: The drug is available in several countries across Europe, Asia, and South America under various brand names, subject to local regulatory approvals and prescribing restrictions.
Safety and adverse effects
- Cardiovascular: The most notable risk associated with sertindole is QT interval prolongation, which can predispose patients to torsades de pointes and ventricular arrhythmias. Baseline and periodic electrocardiograms (ECGs) are recommended, especially in patients with pre‑existing cardiac disease or electrolyte disturbances.
- Metabolic: Weight gain, hyperglycemia, and dyslipidemia have been reported, though the incidence appears lower than that of some other atypical antipsychotics.
- Neurological: Extrapyramidal symptoms (EPS) such as akathisia, parkinsonism, and dystonia are less frequent than with typical antipsychotics but may still occur. Seizure risk is considered low.
- Other: Sedation, orthostatic hypotension (due to α₁‑adrenergic blockade), and anticholinergic effects (dry mouth, constipation) have been observed.
Contraindications and precautions
- Known hypersensitivity to sertindole or any of its excipients.
- History of congenital long‑QT syndrome, recent myocardial infarction, or uncontrolled arrhythmias.
- Concurrent use of other QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics) is generally discouraged.
- Caution is advised in patients with hepatic impairment because of reduced metabolic clearance.
Drug interactions
- CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase sertindole plasma concentrations, raising the risk of cardiac toxicity.
- CYP3A4 inducers (e.g., carbamazepine, rifampicin) can lower sertindole levels, potentially diminishing efficacy.
- Co‑administration with other QT‑prolonging drugs magnifies arrhythmic risk and warrants ECG monitoring.
Pharmacological research
- Ongoing investigations have examined sertindole’s effect on cognitive deficits in schizophrenia and its comparative safety profile relative to other atypical antipsychotics.
- Post‑marketing surveillance data continue to inform risk‑benefit assessments, particularly concerning cardiac safety.
Chemistry
- IUPAC name: (3S,5R)-5-[(4-Fluorophenyl)amino]‑2‑hydroxy‑4‑[(1R,2S)-2‑(pyridin‑2‑yl)‑1‑piperidinyl]‑6‑methyl‑1‑benzopyran‑3‑carboxylic acid.
- Molecular formula: C₂₅H₂₉FN₂O₃.
- Molecular weight: 420.50 g·mol⁻¹.
Societal and clinical considerations
- The need for regular cardiac monitoring limits the drug’s practicality in primary‑care settings lacking immediate ECG capabilities.
- In jurisdictions where sertindole is available, prescribing guidelines often require enrollment in a controlled‑use programme to ensure adherence to safety monitoring protocols.
- Cost considerations vary; in several European markets, sertindole is less expensive than newer atypical agents, influencing prescribing patterns when patients are contraindicated for other drugs.
References
- European Medicines Agency. “Assessment report for sertindole.” 2023.
- Kane, J. M., et al. “Efficacy and safety of sertindole in acute schizophrenia: a double‑blind, placebo‑controlled trial.” Schizophrenia Research 2008.
- Haddad, P. M., & Anderson, I. M. “Antipsychotic drugs and cardiac risk.” Lancet Psychiatry 2019.
